PSMA PET has shown advantages in re-staging in BCR patients (9), as well as for the primary staging in initial diagnosed prostate cancer (10). Recently many studies have indicated that PSMA-positive ganglia represent a potential diagnostic pitfall for nuclear medicine physicians (11–14). This evidence concerns the gene FOLH1 and prostate cancer.